ABIONYX Pharma Announces €1.8 Million Capital Increase

ABIONYX Pharma has launched a capital increase of approximately €1.8 million, aimed at strengthening its financial position. This move involves canceling preferential subscription rights, allowing specific individuals to acquire new shares. A total of 580,643 new shares will be issued with a subscription price set at €3.10, a slight discount from the closing price prior to the issuance decision.

This initiative, sanctioned by the Board of Directors, seeks to extend the company's financial visibility until the end of 2026 and support ongoing projects, including the SEPSIS initiative under France 2030. Existing and new family shareholders have already pledged to contribute €1 million, constituting 55.6% of the capital increase.

The new shares, representing about 1.66% of previously outstanding shares, are expected to commence trading on December 19, 2025, on Euronext.